A teenager with atopic dermatitis presented with several painless, flesh-colored papules limited to the trunk. Dermoscopy and biopsy show selective loss of elastic fibers after prior molluscum contagiosum. What’s your diagnosis?
Emails and interviews show CDC scientists were sidelined during the West Texas surge, leaving local officials without guidance as cases spread across the US and into Mexico.
A long-term clinical study finds that the biologic therapy nemolizumab, when used with topical corticosteroids, continues to improve itch, sleep, and skin symptoms in prurigo nodularis patients over 68 weeks.
Thai investigators test a botanical emulgel formulation to identify early safety signals related to skin irritation and allergenicity before advancing to patient trials.
The number of visits to dermatologists for atopic dermatitis and eczema may have increased during the summer months of 2023 following the Canadian wildfires.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Discover the potential of cendakimab, an anti–interleukin-13 monoclonal antibody, to improve symptoms in adult patients with moderate to severe atopic dermatitis, as demonstrated in a recent phase II clinical trial published in JAMA Dermatology.
Topical delgocitinib improved eczema severity scores and caused fewer adverse events than oral alitretinoin in adults with severe chronic hand eczema, according to a phase 3 study.
From new conferences and OCT systems to the links between pediatric uveitis and early-onset atopic dermatitis, these are the news stories and studies that caught our attention this week…